Veröffentlichungen

Originalarbeiten, Bücher, Buchkapitel und Übersichtsartikel von Prof. Marcus Maurer

Verwendung: Beginnen Sie mit einer Übersicht über alle Publikationen. Verwenden Sie Tag-Links, um markierte Dokumente aufzulisten oder eine ganze Kategorie aufzulisten, z.B. Original Work (Originalarbeiten), Books (Bücher), Book Chapters (Buchkapitel), Reviews (Übersichtsartikel). Wenn Sie wissen, was Sie suchen, dann geben Sie diesen Begriff in das Suchfeld ein.

Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background Therapy

Filename 211. Casale et al., Similar eff. omalizumab ciu csu, JACI Pract. 2015.pdf
Filesize 550,92 kB
Version o.211
Date added Juli 29, 2020
Downloaded 0 times
Category Original Work
Tags Antihistamine, Chronic idiopathic, Chronic spontaneous, hive, itch, omalizumab, Pruritus, urticaria, wheal
Authors Casale, T. B., Bernstein, J. A., Maurer, M. Saini, S. S., Trzaskoma, B., Chen, H., Grattan, C., Gimenèz-Arnau, A., Kaplan, A. P., and Rosén, K.
Citation Casale, T. B., Bernstein, J. A., Maurer, M. Saini, S. S., Trzaskoma, B., Chen, H., Grattan, C., Gimenèz-Arnau, A., Kaplan, A. P., and Rosén, K.: Similar efficacy with Omalizumab in chronic idiopathic/spontaneous urticaria despite different background therapy. J. Allergy Clin. Immunol. Pract. 2015: 3; 743-750.
Corresponding authors Rosén, K.
DocNum O.211
DocType PDF
Edition; Page 3; 743-750
IF 5.42
Publisher J. Allergy Clin. Immunol. Pract.
ReleaseDate 2015

Background: Data from the 3 omalizumab pivotal trials inpatients with chronic idiopathic urticaria/chronic spontaneous urticaria (CIU/CSU) represent the largest database of patients reported to date with refractory disease (omalizumab, n[733;placebo, n[242).

Objective: The objective of this study was to compare results from ASTERIA I and II, which included only approved doses ofH1-antihistamine as background therapy based on regulatory authority requirements, to those from GLACIAL, which permitted higher doses of H1-antihistamines as well as other types of background therapy, in aposthocanalysis.

Methods: Efficacy data from the placebo, omalizumab 150-mg, and omalizumab 300-mg treatment arms of ASTERIA I andII were pooled and analyzed (n[162 and n[160, respectively). The 300-mg treatment arm analyses were compared with the analysis of data from GLACIAL (n[252) using analysis of covariance models. The key efficacy endpoint was change from baseline to week 12 in mean weekly itch severity score (ISS);

 

(Last update: 12.2023)

Number of original publications in peer-reviewed journals:580
Number of reviews in peer-reviewed journals:210
Number of publications (original work and reviews) in peer-reviewed journals:790
Cumulative IF for original publications in peer-reviewed journals:4196.39
Cumulative IF for reviews in peer-reviewed journals:1409.32
Cumulative IF of publications (original work & reviews) in peer-reviewed journals:5605.71
Total number of citations: 36,836, h-index: 99 (Web of Science December 2023)36836

Download-Information

Um die angebotenen Veröffentlichungen herunterladen zu können, müssen Sie sich einloggen. Wenn Sie das Login nicht kennen, schreiben Sie mir bitte Ihre Anfrage.